Ben Lindenmuth

Ben Lindenmuth is a seasoned professional in the biopharmaceutical industry with extensive experience in process development and CMC leadership. Currently serving as Senior Director and CMC Lead at Ultragenyx Pharmaceutical Inc. since September 2018, Ben oversees biologics CMC teams for pre-clinical and early clinical-stage programs. Prior to this, Ben held multiple roles at Bayer HealthCare from July 2011 to August 2018, including Director and Associate Director of Process Development, where critical technical projects supported a commercial recombinant protein manufacturing process generating over $1 billion in annual sales. Ben's earlier experience includes a Principal Engineer role focused on downstream recovery processes and interaction with various departments. Academic credentials include a Ph.D. in Chemical Engineering from the University of California, Davis, and a Certificate in Strategic Decision and Risk Management from Stanford University.